Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients.
Future Microbiol
; 17: 339-350, 2022 03.
Article
in English
| MEDLINE | ID: covidwho-1686353
ABSTRACT
Aims:
Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients &methods:
In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results &conclusions:
All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration NCT04482686 (ClinicalTrial.gov).Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Ivermectin
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Future Microbiol
Journal subject:
Microbiology
Year:
2022
Document Type:
Article
Affiliation country:
Fmb-2022-0014
Similar
MEDLINE
...
LILACS
LIS